Table 2.
Parameter | Rates of Unilateral PA (%) | P | |
---|---|---|---|
Age, years | <43 | 10.9 | 0.022* |
44-51 | 9.6 | ||
52-60 | 15.2 | ||
≥61 | 14.7 | ||
HT duration, years | <1 | 5.5 | <0.001* |
1-3 | 7.0 | ||
4-9 | 12.3 | ||
≥10 | 23.7 | ||
Creatinine, mg/dL | <0.6 | 8.1 | <0.001* |
0.6-0.70 | 8.2 | ||
0.71-0.83 | 12.3 | ||
≥0.84 | 21.6 | ||
Serum K+, mEq/l | <3.6 | 34.2 | <0.001* |
3.6-3.8 | 10.7 | ||
3.9-4.0 | 7.4 | ||
≥4.1 | 5.1 | ||
ARR, pg/ml per ng/ml/h | <298 | 6.0 | <0.001* |
298-442 | 7.1 | ||
443-742 | 11.2 | ||
≥743 | 26.2 | ||
PAC, pg/ml | <123 | 2.6 | <0.001* |
123-161 | 9.5 | ||
162-225 | 12.6 | ||
≥226 | 25.4 |
Cuzick’s nonparametric test was performed to assess trends across ordered groups. Asterisks (*) indicate significant differences (P <0.05). ARR, aldosterone-to-renin ratio; HT, hypertension; PA, primary aldosteronism; and PAC, Plasma aldosterone concentration.